DelveInsight’s, “Complicated Urinary Tract Infections Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Complicated Urinary Tract Infections pipeline landscape. It covers the Complicated Urinary Tract Infections pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Complicated Urinary Tract Infections pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ Complicated Urinary Tract Infections Pipeline Outlook Report
Key Takeaways from the Complicated Urinary Tract Infections Pipeline Report
- In August 2025, Menarini Group announced a clinical trial is to assess the pharmacokinetic (PK) and safety and tolerability of Vaborem ( fixed combination of meropenem and vaborbactam) in the paediatric population aged from 3 months to < 18 years with complicated urinary tract infection (cUTI) including acute pyelonephritis (AP) in need of hospitalisation and intravenous (IV) antibiotic administration.
- DelveInsight’s Complicated Urinary Tract Infections pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Complicated Urinary Tract Infections treatment.
- The leading Complicated Urinary Tract Infections Companies such as Spero Therapeutics, Jiangsu Hengrui Medicine Co., Everest Medicines, NeuroRx Inc., Pfizer and others.
- Promising Complicated Urinary Tract Infections Pipeline Therapies such as Ceftazidime -avibactam, Cefepime, Eravacycline, Ertapenem, CXA-101, Sulopenem, NXL104/ceftazidime, Imipenem/Cilastatin and others.
Learn how leading Complicated Urinary Tract Infections Companies are positioning themselves for success in the evolving pharmaceutical market—access the full report today!” @ Complicated Urinary Tract Infections Clinical Trials Assessment
Complicated Urinary Tract Infections Emerging Drugs Profile
- TBP-PI-HBr: GSK/ Spero Therapeutics
Tebipenem pivoxil hydrobromide (HBr) is an orally administered carbapenem antibiotic developed by Spero Therapeutics, designed to address serious bacterial infections such as complicated urinary tract infections (cUTIs), including pyelonephritis. As the first oral carbapenem in development, tebipenem HBr offers a potential alternative to intravenous therapy, providing broad-spectrum antibacterial activity against multidrug-resistant Gram-negative pathogens. Its oral formulation supports earlier hospital discharge and improved outpatient management, making it a promising option in the evolving landscape of antimicrobial resistance and infection control. Currently, the drug is in the Phase III stage of its development for the treatment of Complicated Urinary Tract Infections.
- NRX-101: NeuroRx, Inc.
NRX-101 is an investigational oral medication that combines D-cycloserine, an NMDA receptor antagonist, with lurasidone, an atypical antipsychotic, and is being explored for use in treating complicated urinary tract infections (cUTIs). The formulation leverages the antimicrobial properties of D-cycloserine, which has shown activity against resistant bacterial strains, and the neuroprotective and mood-stabilizing effects of lurasidone to potentially address both infection and associated symptoms such as delirium or behavioral disturbances in vulnerable populations. Its oral route of administration offers the advantage of outpatient treatment potential, especially in patients requiring step-down therapy after initial intravenous antibiotics. Currently, the drug is in Phase II stage of its development for the treatment of Complicated Urinary Tract Infections.
- PF-07612577: Pfizer
PF-07612577 is an investigational antibiotic combination developed for the treatment of complicated urinary tract infections (cUTIs). It includes an intravenous β-lactamase inhibitor paired with a cephalosporin antibiotic, designed to combat multidrug-resistant gram-negative bacteria, including extended-spectrum β-lactamase (ESBL) and carbapenem-resistant Enterobacterales. This combination works by inhibiting bacterial enzymes that degrade β-lactam antibiotics, thereby restoring the efficacy of the cephalosporin component. PF-07612577 aims to provide a potent treatment option for patients with limited alternatives due to antimicrobial resistance, making it especially valuable in hospital settings where resistant pathogens are a growing concern. Currently, the drug is in Phase I stage of its development for the treatment of Complicated Urinary Tract Infections.
The Complicated Urinary Tract Infections Pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Complicated Urinary Tract Infections with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Complicated Urinary Tract Infections Treatment.
- Complicated Urinary Tract Infections Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Complicated Urinary Tract Infections Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Complicated Urinary Tract Infections market.
From early-stage research to late-phase Complicated Urinary Tract Infections Clinical Trials, our analysis covers key companies, innovative treatment approaches, and the next wave of Emerging Drugs. Don’t miss this opportunity to stay informed—download now! @ Complicated Urinary Tract Infections Treatment Drugs
Complicated Urinary Tract Infections Companies
Spero Therapeutics, Jiangsu Hengrui Medicine Co., Everest Medicines, NeuroRx Inc., Pfizer and others.
Complicated Urinary Tract Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Complicated Urinary Tract Infections Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Stay updated with the latest Complicated Urinary Tract Infections Pipeline Insights—download our report for a deep dive into the next generation of therapeutics! @ Complicated Urinary Tract Infections Market Drivers and Barriers, and Future Perspectives
Scope of the Complicated Urinary Tract Infections Pipeline Report
- Coverage- Global
- Complicated Urinary Tract Infections Companies- Spero Therapeutics, Jiangsu Hengrui Medicine Co., Everest Medicines, NeuroRx Inc., Pfizer and others.
- Complicated Urinary Tract Infections Pipeline Therapies- Ceftazidime -avibactam, Cefepime, Eravacycline, Ertapenem, CXA-101, Sulopenem, NXL104/ceftazidime, Imipenem/Cilastatin and others.
- Complicated Urinary Tract Infections Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Complicated Urinary Tract Infections Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Find answers in our latest Complicated Urinary Tract Infections Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs. Download now to stay at the forefront of pharmaceutical innovation!” @ Complicated Urinary Tract Infections Emerging Drugs and Companies
Table of Contents
- Introduction
- Executive Summary
- Complicated Urinary Tract Infections: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Complicated Urinary Tract Infections– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- TBP-PI-HBr: GSK/ Spero Therapeutics
- Mid Stage Products (Phase II)
- NRX-101: NeuroRx, Inc.
- Early Stage Products (Phase I)
- PF-07612577: Pfizer
- Preclinical and Discovery Stage Products
- Drug Name: Company Name
- Inactive Products
- Complicated Urinary Tract Infections Key Companies
- Complicated Urinary Tract Infections Key Products
- Complicated Urinary Tract Infections- Unmet Needs
- Complicated Urinary Tract Infections- Market Drivers and Barriers
- Complicated Urinary Tract Infections- Future Perspectives and Conclusion
- Complicated Urinary Tract Infections Analyst Views
- Complicated Urinary Tract Infections Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/complicated-urinary-tract-infections-pipeline-insight